Defunct Company
Total Trials
7
As Lead Sponsor
6
As Collaborator
1
Total Enrollment
815
NCT00286377
Safety and Efficacy Study of Prosaptide to Treat Neuropathic Pain in HIV-Positive Patients
Phase: Phase 2
Role: Lead Sponsor
Start: Sep 30, 2003
Completion: Dec 31, 2004
NCT00080210
A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional Therapy
Start: Mar 31, 2004
Completion: Feb 28, 2005
NCT00111657
Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout
Role: Collaborator
Start: Dec 31, 2004
Completion: Jul 31, 2009
NCT00325195
Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout
Phase: Phase 3
Start: May 31, 2006
Completion: Dec 31, 2007
NCT01356498
Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout
Start: Dec 31, 2006
Completion: Jan 31, 2010
NCT00675103
Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients
Start: May 31, 2008
Completion: Apr 30, 2009
NCT01739660
Study to Assess Pegloticase (KRYSTEXXA®) in Patients on Hemodialysis
Phase: Phase 1
Start: Dec 31, 2012
Completion: Apr 30, 2013